We begin this week's episode by breaking down the recent phase III trial on voxeletor in sickle cell disease with Dr. Sven Olson of OHSU. Next, we feature guest Dr. David Steensma of the Dana-Farber Cancer Institute in a far-reaching interview on being well-read, running a small lab, humanizing cancer, learning from our past use of erythropoiesis-stimulating agents, understanding the headache of contract research organizations, defining cancer, and more!

Voxeletor in Sickle Cell: doi.org/10.1056/NEJMoa1903212

Don't Mention It: doi.org/10.1200/JCO.2008.17.7238

The Raven: doi.org/10.1200/JCO.2017.76.3458

Erythropoietin Use in Cancer: doi.org/10.1200/JCO.2005.05.036

Contract Research Organizations: doi.org/10.1002/cncr.29994

Back us on Patreon! www.patreon.com/plenarysession